Cost-effectiveness of the MitraClip device in secondary mitral regurgitation: comment upon the article by Estler et al.
暂无分享,去创建一个
[1] S. Stock,et al. Cost-effectiveness of the MitraClip device in German heart failure patients with secondary mitral regurgitation , 2022, The European Journal of Health Economics.
[2] M. Mack,et al. Cost-effectiveness of transcatheter edge-to-edge repair in secondary mitral regurgitation , 2022, Heart.
[3] M. Mack,et al. 3-Year Outcomes of Transcatheter Mitral Valve Repair in Patients With Heart Failure. , 2021, Journal of the American College of Cardiology.
[4] Immature survival data for cancer drugs impacts NICE decisions , 2021, PharmacoEconomics & Outcomes News.
[5] M. Metra,et al. COAPT-Like Profile Predicts Long-Term Outcomes in Patients With Secondary Mitral Regurgitation Undergoing MitraClip Implantation. , 2020, JACC. Cardiovascular interventions.
[6] L. Frankenstein,et al. An analysis of the cost-effectiveness of transcatheter mitral valve repair for people with secondary mitral valve regurgitation in the UK , 2020, Journal of medical economics.
[7] M. Mack,et al. Cost-Effectiveness of Transcatheter Mitral Valve Repair versus Medical Therapy in Patients with Heart Failure and Secondary Mitral Regurgitation: Results from the COAPT Trial. , 2019, Circulation.
[8] B. Bouma,et al. Comparison of Outcome After Percutaneous Mitral Valve Repair With the MitraClip in Patients With Versus Without Atrial Fibrillation. , 2017, The American journal of cardiology.
[9] P. Voisine,et al. Transcatheter Mitral-Valve Repair in Patients with Heart Failure. , 2019, The New England journal of medicine.